The data company has ambitions to accelerate precision drug discovery and development by selling its customer data that comprises patients' complete healthcare experiences.
The Swiss biotech is developing a personalized neoantigen vaccine and working with the NCI to test the ability of an off-the-shelf vaccine to prevent cancer in those with Lynch syndrome.
In a Cancer Discovery paper, MSK researchers charted impressive growth in FDA-approved precision oncology drugs and eligibility but acknowledged major limitations in the field.
The firm believes its investigational antibody-drug conjugate Dato-DXd could replace chemotherapy in certain breast and lung cancer treatment settings.
Oncology product sales climbed 33 percent during the third quarter of this year, though overall sales remained flat compared to Q3 2022.
Pluvicto monotherapy recently benefitted a similar prostate cancer population in another trial, but researchers anticipate efficacy and safety advantages with the immunotherapy combination.
The Swiss drugmaker also reported revenue increases across other precision oncology products including its breast cancer drug Kisqali.
Metastatic prostate cancer patients who received prior hormone therapy benefited from Novartis' PSMA-targeted radiopharmaceutical in the PSMAfore trial.
After the robust activity seen in 2023 with Opdivo-Yervoy in colorectal cancer, Opdivo-relatlimab garnered attention this year with a 100 percent response rate.
As Iovance awaits the regulatory fate of lifileucel in refractory melanoma, oncologists touted a subset analysis supporting its standard use in mucosal melanoma.